Skip Navigation

European Heart Journal 2004 25(6):454-456; doi:10.1016/j.ehj.2004.02.005
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kastrati, A
Right arrow Articles by Schömig, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kastrati, A
Right arrow Articles by Schömig, E
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Are we making efficient use of clopidogrel?

A Kastrati* and A Schömig

Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität München, Lazarettstr. 36, Munich, Germany

E Schömig

Institut für Pharmakologie, Klinikum der Universitat zu Köln, Cologne, Germany

* Correspondence to: Tel.: +49-8912184577; fax: +49-8912184593
E-mail address: kastrati@dhm.mhn.de

The first 10% of the full text of this article appears below.

This editorial refers to "Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions"1 by Lepäntalo et al. on page 476

Blood platelets play a major role in the occurrence of thrombotic complications after percutaneous coronary interventions (PCI). Introduction of the thienopyridine drug ticlopidine as an adjunctive antiplatelet therapy has considerably improved the outcome of patients who undergo PCI.1 Thienopyridines act via blockade of one (P2Y12) of the three adenosine 5-diphosphate (ADP) receptors, reducing ADP-induced platelet activation and aggregation.2 Concerns about the side effects of ticlopidine, especially severe neutropenia and thrombotic thrombocytopenic purpura, were a major reason for the rapid replacement of this drug with clopidogrel. Another important limitation of ticlopidine is its delayed . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions
Aino Lepäntalo, Kari S Virtanen, Juhani Heikkilä, Ulla Wartiovaara, and Riitta Lassila
EHJ 2004 25: 476-483. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 QJMHome page
R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, and L. Testa
Interaction between statins and clopidogrel: is there anything clinically relevant?
QJM, December 1, 2008; 101(12): 915 - 925.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Kastrati, N. von Beckerath, A. Joost, G. Pogatsa-Murray, O. Gorchakova, and A. Schomig
Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy
Circulation, October 5, 2004; 110(14): 1916 - 1919.
[Abstract] [Full Text] [PDF]